La lectura interpretativa del antibiograma: Una herramienta para predecir la resistencia bacteriana en el laboratorio de microbiología de rutina

Colombia Medica

Volumn 33, Issue 4, 2002, Pages 179-193

  Crespo, María Del Pilar ^a  

^a UNIVERSIDAD SANTIAGO DE CALI   (Colombia)

Author keywords

Bacterial resistance; Mechanisms; Phenotipes; Profiles; Susceptibility

Indexed keywords

EID: 52649162897     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Leclercq R. Concepts of expert system for the interpretation of antimicrobial susceptibility test. VITEK 2 References 1997; 1 Suppl: 26-28.
2. Betriu C, Picazo JJ. Bacterias Gram positivas resistentes a antimicrobianos en Latino-américa. Infect Dis Clin Pract 2002; Suppl: 13-21.
3. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Eng J Med 1999; 340: 493-501.
4. Huycke MM, Sahm DF, Gilmore MS. Multiple drug resistant enterococci: the nature of the problem and a agenda for the future. EID 1998; 4: 239-249.
5. Reyes, H, Navarro P, Reyes H. Resistencia bacteriana a los antimicrobianos. Antib Inf 1998; 2: 12-19.
6. Isenberg HD. Essential procedures for clinical microbiology: antimicrobial susceptibility testing. Washington: ASM Press; 1998. p. 205-254.
7. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 4: 557-584.
8. Chartrand S, Thompson K, Sanders C. Antibiotic-resistant Gram negative bacillary infections. Sem Pediatr Infect Dis 1996; 7: 187-203.
9. Pitout J, Sanders CC, Sanders E. Antimicrobial resistance with focus on β-lactam resistance in Gram-negative bacilli. Am J Med 1997; 103: 51-59.
10. Nikaido H. Antibiotic resistance caused by Gram negative multidrug efflux pumps. Clin Infect Dis 1998; 27 Supl 1: 32-41.
11. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 2000.
12. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 2000.
13. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego; 2002.
14. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego; 2002.
15. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego; 2002.
16. Gove EW, Marcus L. An alternative method for confirming the presence of AmpC and extended-spectrum β-lactamases (ESBLs) from clinical isolates using etest strips. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 1999.
17. Negri MC, Baquero F. In vitro selective concentration of cefepime and ceftazidime for AmpC hyperproducer E cloacae variants. Clin Microb Infect 1999; 5: 525-528.
18. Thomson K. Controversies about extended-spectrum and Ampc β-lactamases. MMWR 2001; 7: 1-7.
19. Reunión de consenso. La aparición de microorganismos productores de ESBL en América Latina: recomendaciones para su control y tratamiento. Infect Dis Clin Pract 2001; Suppl: 3-32.
20. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
21. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002, 49: 229-233.
22. Pechère JC, Köhler T. Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 1999; 5 Supl: 15-18.
23. Nordmann P, Guibert M. Extended-spectrum β-lactamases in Ps. aeruginosa. J Antimicrob Chemother 1998, 42: 128-131.
24. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved standard M7-A4. Wayne: National Committee for Clinical Laboratory Standars; Vol 21, N° 1, January 2001.
25. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002.
26. Marumo K, Takeda A, Nakamura Y, Nakya K. Detection of OXA β-lactamase in Ps. aeruginosa isolates by genetic methods. J Antimicrob Chemother 1999; 43: 187-193.
27. Stunt RA, Thomson CJ, Paine DJ, Amyes SGB. A study of the mechanisms involved in IMP resistance in Ps. aeruginosa isolates from Japan. J Antimicrob Chemother 1998; 42: 272-273.
28. Yu WL, Pfaller MA, Winokur PL, Jones RN. Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan. EID 2002; 8: 1-5.
29. Yong D, Lee, K, Yum JH, Shin HB, Russolin GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo-β-lactamase-producing clinical isolates of Pseudomonas spp and Acinetobacter spp. J Clin Microbiol 2002; 40: 3798-3801.
30. Stratton CW. Extended-spectrum β-lactamases: dilemmas in detection and therapy. Antimicorbics and Infectious Diseases. Newsletter 1997; 16: 57-61.
31. Lepper PM, Grusa E, Reichi H, Högel J, Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2920-2925.
32. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacif Region. Clin Infec Dis 2001; 32 Suppl 2: 94-103.
33. Rice L. Successful interventions for Gram negative resistance to extended spectrum β-lactam antibiotics. Pharmacotherapy 1999; 19: 120-128.
34. Okeke IN, Lamiranka A, Edelman R. Socio-economic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. EID 1999; 5: 18-27.